A Comparison Between the Intubating Laryngeal Tube Suction and the Ambu AuraGain
NCT ID: NCT05347680
Last Updated: 2022-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2019-09-19
2021-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparison Between the Intubating Laryngeal Tube Suction and the Ambu AuraGain
NCT02878005
The New Intubating Laryngeal Tube Suction-Disposable
NCT02884843
Prospective Comparison of Oral Intubation Via - Ambu® Aura Gain™ vs Slotted Guedel Tubus
NCT02570269
Ambu Aura-i Laryngeal Mask Versus Air-Q Intubating Laryngeal Airway for Tracheal Intubation in Adults
NCT02226211
Ambu®AuraGain™ Versus I-gel® in Obese Patients
NCT03110393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Detailed Description: The intubating Laryngeal Tube Suction-Disposable (iLTS-D) (VBM Medizintechnik GmbH, Sulz, Germany) is a new updated version of the Laryngeal Tube-Suction Disposable (LTS-D) It has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an Endotracheal Tube (ETT) with fiberoptic guidance. Similarly as in to the LTS-D, the iLTS-D also has a separate channel for the purpose of placement of gastric tubes placement up to a size of 18 Fr.
The iLTS-D comes in one size. According to the depth of insertion, this device is equivalent to size 4 for patients height 175 to 190 cm tall, or size 5 for patients taller than 190 cm. The iLTS-D is provided by the manufacturer with a compatible 7.5 mm ETT and with a plastic stabilizer for removal of the device.
The current randomized study was designed to assess the success rate fiberoptic endotracheal intubation using iLTS-D, in comparison with the and Ambu® AuraGain™ in adult patients under general anesthesia
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intubating laryngeal Tube Suction
Fiberoptic Intubation through intubating laryngeal Tube Suction
Intubating Laryngeal Tube Suction
Intubating Laryngeal Tube Suction
Ambu AuraGain Laryngeal Mask
Fiberoptic Intubation through Ambu AuraGain Laryngeal Mask
Ambu AuraGain Laryngeal Mask
Ambu AuraGain Laryngeal Mask
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intubating Laryngeal Tube Suction
Intubating Laryngeal Tube Suction
Ambu AuraGain Laryngeal Mask
Ambu AuraGain Laryngeal Mask
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cervical pathology
* pregnancy
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bnai Zion Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luis Gaitini, Prof
Role: PRINCIPAL_INVESTIGATOR
Bani Zion Medical Center Haifa ISRAEL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Luis A Gaitini M.D.
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0132-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.